KDR and lung adenocarcinoma: In addition, it has been shown that antiangiogenic therapy targeting the components of the VEGFA/VEGFR2 pathway was effective in the treatment of lung adenocarcinoma (LAC), but biomarkers are required to identify the target group of patients.